Difference between revisions of "Paroxetine-agomelatine"
From Psychiatrienet
| Line 5: | Line 5: | ||
{{downparox}} | {{downparox}} | ||
| start = | | start = | ||
| − | * '''Day | + | * '''Day 16:''' start agomelatine in a dosage of 25 mg/day. |
| − | * '''Day | + | * '''Day 31:''' If necessary, gradually increase dosage of agomelatine to target dose. |
| info = | | info = | ||
* An extra reduction week to paroxetine 2,5 mg/day is sometimes necessary. | * An extra reduction week to paroxetine 2,5 mg/day is sometimes necessary. | ||
* Low doses of paroxetine can be given by a paroxetine-solution. | * Low doses of paroxetine can be given by a paroxetine-solution. | ||
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref> | <ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref> | ||
| − | {{ | + | {{SSRI14d}} |
}} | }} | ||
Revision as of 13:56, 21 October 2015
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Switch medication from paroxetine to agomelatine.[1] [2]
Stop paroxetine - Day -7: reduce dosage of paroxetine to 20 mg/day, if this dosage is > 20 mg/day.
- Day 0: dosage of paroxetine is 20 mg/day.
- Day 1: reduce dosage of paroxetine to 10 mg/day.
- Day 8: reduce dosage of paroxetine to 5 mg/day.
- Day 15: stop administration of paroxetine.
Start agomelatine- Day 16: start agomelatine in a dosage of 25 mg/day.
- Day 31: If necessary, gradually increase dosage of agomelatine to target dose.
More information- An extra reduction week to paroxetine 2,5 mg/day is sometimes necessary.
- Low doses of paroxetine can be given by a paroxetine-solution.
- The reduction of the SSRI doses in 7-14 days could cause emotional instability, headache and flu-like symptoms. One could extend this period.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
